HCPCS code J7665 – Mannitol, administered through an inhaler, 5 mg

Key Takeaways

HCPCS code J7665 represents mannitol inhalation powder (Aridol), 5 mg per capsule, used specifically for the bronchial provocation challenge test, not for therapeutic mannitol use.

Bill J7665 per capsule administered, not per kit; include the 11-digit NDC on every Medicare Part B claim or the claim will deny.

Pair J7665 with CPT 94070 for the bronchospasm provocation procedure and ICD-10 J45.x (asthma) or R06.2 (wheezing) to establish medical necessity.

Pabau’s claims management software supports NDC field capture and buy-and-bill tracking workflows for physician-administered drug claims like J7665.

HCPCS code J7665: official descriptor and code definition

HCPCS code J7665 is a Level II J-series drug code maintained by the Centers for Medicare and Medicaid Services (CMS) for mannitol administered through an inhaler, defined at 5 mg per capsule. The code covers the drug itself, not the administration procedure or professional interpretation of results.

J7665 is a product-specific code assigned to Aridol. There is no equivalent code for other mannitol formulations used in bronchial challenge testing. Billers who attempt to use an unclassified drug code such as J7799 in place of J7665 risk denial because J7799 requires manufacturer pricing documentation that does not apply when a specific J-code exists.

What J7665 covers: clinical scope and intended use

J7665 covers the mannitol inhalation powder (Aridol) dispensed during a bronchial provocation challenge test, a diagnostic procedure used to assess airway hyperresponsiveness in patients with suspected or poorly controlled asthma. The code applies when a physician or qualified provider administers graded doses of mannitol via a dry-powder inhaler, with spirometry performed between doses to detect a significant drop in FEV1.

• Covered clinical scenario: Diagnostic mannitol challenge to assess airway hyperresponsiveness where spirometry alone has been inconclusive
• Covered clinical scenario: Evaluation of exercise-induced or occupational asthma when conventional workup is negative
• Covered clinical scenario: Confirmation of asthma control or response to therapy in research and specialist settings
• Not covered: Therapeutic mannitol use (e.g., for mucociliary clearance in cystic fibrosis, which uses a different product and dosing protocol)

Only the drug component falls within J7665. The pulmonary function testing and physician interpretation services are billed separately under companion CPT codes.

Companion CPT codes to bill alongside J7665

A complete mannitol challenge test claim requires both the J7665 drug code and at least one CPT procedure code. Billing J7665 alone, without an accompanying procedure code, is a leading cause of claim denial because the drug charge appears unsupported by a billable clinical service.

CPT 94070 is the standard companion code confirmed in Methapharm Respiratory’s US coding guide for the Aridol mannitol challenge protocol. The applicability of CPT 94617 specifically to mannitol (as distinct from physical exercise) should be verified against your MAC’s local coverage guidance before routine use. See the AAPC HCPCS code lookup for current companion code edits and bundling rules.

How to bill J7665: units, NDC, and claim submission requirements

Correct unit billing and NDC documentation are the two most critical technical elements of a J7665 claim. Getting either wrong results in an automatic denial. Establishing a medical billing workflow that captures these fields at the point of administration prevents most downstream claim errors.

Unit definition

J7665 is billed per 5 mg capsule administered, not per kit. The Aridol bronchial challenge kit contains multiple capsules of varying doses ( mg, 5 mg, 10 mg, 20 mg, 40 mg, 80 mg, 160 mg), but J7665 covers only the 5 mg capsules. Bill one unit of J7665 for each 5 mg capsule actually inhaled by the patient during the test. Do not bill the entire kit quantity; document the exact number of capsules used in the procedure note.

NDC requirement

Medicare requires the 11-digit National Drug Code on all Part B drug claims. Submitting a J7665 claim without the NDC is a guaranteed denial. The NDC should be recorded from the Aridol packaging at the time of administration. Verify the current NDC against the product label before each claim submission, as NDC numbers can change with packaging updates. Place the NDC in field 24A on the CMS-1500 or Loop 2410 on the 837P electronic claim file.

Eligible places of service

For physician office billing, J7665 follows a buy-and-bill model. The practice acquires Aridol from the distributor, administers it during the challenge test, and bills Medicare for reimbursement. Accurate drug acquisition records are part of the required documentation for superbill and audit purposes. Using claims management software with NDC field support reduces the risk of omitting the NDC at claim generation.

J7665 ICD-10 diagnosis codes: required pairings for medical necessity

Every J7665 claim requires a supporting ICD-10-CM diagnosis code that establishes medical necessity for the bronchial provocation test. Submitting J7665 with an unspecified or unrelated diagnosis code is among the most frequent denial triggers. After verifying insurance eligibility and coverage, confirm the diagnosis code before claim submission.

Verify against any active Local Coverage Determination from your Medicare Administrative Contractor before relying on secondary symptom codes as the primary diagnosis. MAC policies on acceptable ICD-10 pairings for bronchial provocation testing vary.

J7665 fee schedule and reimbursement rates

Medicare reimburses J7665 under Average Sales Price (ASP) methodology, the standard payment model for physician-administered Part B drugs. The allowed amount is calculated as ASP plus 6%, updated quarterly by CMS based on manufacturer-reported sales data. This means no static dollar figure published in an article remains accurate beyond the quarter it was written. Understanding revenue cycle management for drug codes requires checking the current ASP file directly.

For the current quarter’s rate, access the CMS Physician Fee Schedule search tool or the CMS ASP drug pricing files published at CMS.gov. Review the electronic remittance advice after each paid claim to confirm the allowed amount and catch any rate discrepancies before the filing deadline.

J7665 Medicare coverage policy

Medicare Part B covers J7665 as a physician-administered drug used in a diagnostic procedure. Coverage applies when the mannitol challenge test is ordered by a physician or qualified non-physician practitioner and is medically necessary for the diagnosis or management of a respiratory condition, primarily asthma evaluation. Medical billing compliance for this code depends on understanding the distinction between Medicare’s standard coverage and Medicare Advantage plan-specific restrictions.

• Traditional Medicare (Parts A/B): Covered under Part B when administered in a physician office or hospital outpatient setting; no specific NCD governs the mannitol challenge test as of current publication, though MAC-level LCDs may apply
• Medicare Advantage: MA plans frequently require prior authorization even for services covered by traditional Medicare; verify PA requirements with the specific plan before scheduling
• Supervising physician: The test must be ordered and the results interpreted by a physician; general direct supervision applies in most outpatient settings
• Referral requirement: Medicare does not require a referral to a specialist for this test, but the ordering documentation should reflect a clinical rationale consistent with the diagnosis codes submitted

Confirm whether an active LCD from your MAC governs bronchial provocation testing. The CGS Medicare coding verification bulletin is a useful reference for the CGS jurisdiction; providers under other MACs should check their MAC’s website directly.

Manage drug claims and billing workflows in one place

Pabau’s claims management tools support NDC capture, buy-and-bill documentation, and HIPAA-compliant record keeping for physician-administered drug codes like J7665.

Book a demo

Common J7665 claim denial reasons and how to fix them

Most J7665 denials fall into a small number of repeatable patterns. Reviewing denial codes in medical billing alongside your remittance advice helps identify which of the categories below is driving rejections in your practice. Structured denial management strategies catch these errors before they age past the timely filing window.

Reviewing how to submit a clean claim for physician-administered drugs reduces first-pass denial rates and avoids the administrative burden of corrected claim resubmissions.

J7665 documentation requirements for claim support

Missing or insufficient documentation is the root cause of most J7665 medical necessity denials. HIPAA-compliant documentation practices require that the medical record support every element of the claim before submission.

• Physician order: Written order for the mannitol inhalation challenge test, including the clinical indication
• Clinical indication note: Documentation of signs and symptoms (wheezing, cough, dyspnea) or prior negative workup supporting the need for the challenge test
• Procedure note: Records the capsule doses administered at each step, patient response at each dose level, and FEV1 readings between doses; must include the total number of 5 mg capsules used
• Drug acquisition record: Invoice or purchase record for the Aridol kit used (required for buy-and-bill audit support)
• Post-test interpretation: Physician’s written interpretation of the challenge test results, including whether airway hyperresponsiveness was demonstrated

Each documentation element maps to a specific audit risk area. A missing physician order creates a medical necessity vulnerability; a missing procedure note leaves the unit count unsupported. Practices performing frequent bronchial challenge tests should use a standardised template that captures all required elements at the point of care.

J7665 vs related codes: avoiding common coding errors

J7665 is frequently confused with several adjacent codes. Using the wrong code results in denial or, worse, overpayment recoupment during audit. The table below maps the most common coding errors seen in revenue cycle management for bronchial provocation billing.

Conclusion

J7665 is a narrow, product-specific code with a clear clinical purpose and a predictable set of billing requirements. Most claim problems trace to three fixable errors: billing units by kit rather than capsule, omitting the NDC, and submitting without a companion CPT code. Practices that build these checks into their pre-submission workflow recover reimbursement faster and spend less time on corrected claims.

Pabau’s claims management software supports NDC documentation and buy-and-bill tracking for physician-administered drug codes. To see how Pabau handles the full billing workflow for pulmonology and specialist practices, book a demo.

Continue your research

Need to understand medical billing fundamentals for drug codes? What is medical billing covers the end-to-end workflow from charge capture through payment posting.

Working through a high denial rate on physician-administered drugs? Denial management in healthcare outlines the structured approach to identifying root causes and reducing first-pass rejection rates.

Want to understand how remittance data can guide your billing process? Electronic remittance advice explains how to read ERA files and use denial reason codes to fix recurring claim errors.

Frequently Asked Questions